Amgen Inc. (AMGN)
| Market Cap | 160.51B |
| Revenue (ttm) | 33.42B |
| Net Income (ttm) | 4.09B |
| Shares Out | 537.20M |
| EPS (ttm) | 7.56 |
| PE Ratio | 39.41 |
| Forward PE | 14.42 |
| Dividend | $9.52 (3.20%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 148,453 |
| Open | 294.67 |
| Previous Close | 297.93 |
| Day's Range | 297.19 - 299.77 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 322.26 (+7.86%) |
| Earnings Date | Feb 4, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $322.26, which is an increase of 7.86% from the latest price.
News
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
Amgen, Inc. (NASDAQ:AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Cla...
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Amgen, Inc. (NASDAQ:AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Develop...
One 'Safer' Buy In 10 February Dogs Of The Dow
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the ...
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
THOUSAND OAKS, Calif. , Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m.
23 Upcoming Dividend Increases, Including 2 Kings
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica...
Amgen: Multiple Strengths, But The Valuation Is A Concern
Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as a ho...
Amgen Stock Has Surged. Here's Where It's Headed Next.
The stock is up 15% since late December.
Amgen: The Charts Didn't Lie, Upgrade To Buy
Amgen is a "buy" due to its strong earnings beat, attractive dividend, and technical chart pattern forecasting positive future performance. I prioritize a balanced approach, focusing on risk and rewar...
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with...
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen Inc.'s Q4 2024 earnings beat expectations, with 11% YoY revenue growth and 13% EPS increase, showcasing robust performance for the company's growth strategy. Amgen's diversified portfolio includ...
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
On Tuesday, Amgen Inc AMGN reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the consensus of $8.9 billion.
Amgen, Inc. (AMGN) Q4 2024 Earnings Call Transcript
Amgen, Inc. (NASDAQ:AMGN) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Globa...
Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold
CNBC's Angelica Peebles joins 'Closing Bell Overtime' with Amgen earnings.
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after...
How To Invest $100,000 In The Ten Cheapest Dow Dividend 100 Stocks
SCHD is the core of this dividend portfolio idea, ranking the best of the top 20 holdings. Stocks must have paid dividends for 10 years, have a market cap of $500M+, and an average daily trading volum...
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today anno...
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Amgen Inc. (NASDAQ:AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Ch...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P.
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinica...